scpharmaceuticals.com (SCPH) Forward P/S Multiple
scPharmaceuticals Inc. complies with basic environmental standards by outsourcing pump production to external partners. The projected price-to-sales ratio visualizes market expectations, where 6.00 shows the current value of the metric. scPharmaceuticals Inc. is implementing the Furoscix system for home treatment of heart failure, reducing hospital expenses. Its status as an innovator and the trust of cardiologists confirm the high value of the therapy for patients.
Metric breakdowns and analytics for scpharmaceuticals.com (SCPH)
- market price and analyst price targets:
- market capitalization details:
- issuer book value statistics:
- debt level and financial liquidity data:
Total Debt to Capital scPharmaceuticals Inc.|SCPH - Long-Term Debt to Capital|Short-Term Debt to Equity scPharmaceuticals|SCPH - Aggregate Debt Obligations|Debt to Book Capitalization Ratio scPharmaceuticals Inc.|SCPH - Company Long-Term Liabilities|Company Short-Term Debts scPharmaceuticals|Quick Ratio scpharmaceuticals.com
- business earnings and investment ratios data:
SCPH - Net Income|Projected Future Earnings scPharmaceuticals Inc.|SCPH - Market Cap to Earnings|Projected Price to Earnings scPharmaceuticals|SCPH - PEG Multiple|Enterprise Value to EBITDA Ratio scPharmaceuticals Inc.|SCPH - Company profit before taxes, interest and amortization|Net earnings per share (EPS TTM) scPharmaceuticals|SCPH - Net earnings per share for the last four quarters|Quarterly EPS earnings growth scpharmaceuticals.com|SCPH - Net earnings per share growth this year|Earnings growth forecast for next year scPharmaceuticals Inc.
- sales volume and revenue information:
Summary company analysis:SCPH (scPharma)
This indicator compares the current market capitalization of scPharmaceuticals Inc. (SCPH) with projected revenue to determine the premium for future growth and the potential acquisition value of the asset. Amid the expansion of the home heart failure treatment segment, the estimated forward P/S reflects how the market values the effectiveness of reducing hospitalization costs, allowing investors to identify business undervaluation or operational risks.
Competitors of scPharmaceuticals Inc. (SCPH)
Price-to-Projected Revenue Ratio Haleon HLN|Market Cap to Expected Sales Ratio Kenvue Inc (KVUE)|Verona Pharma Corp - Forward P/S Multiple|Jyong Bio (MENS) - Forward Price-to-Revenue Multiple|Ligand Pharmaceuticals (LGND) - Price-to-Projected Revenue Ratio|Future Price to Revenue AMRX (amneal.com)|PRGO (Perrigo) - Forward P/S Multiple|ALVO: Forward Price to Sales|Forward P/S Multiple LQDA|Forward P/S Multiple Galapagos Corp (GLPG)|Price-to-Projected Revenue Ratio ANI Pharmaceuticals ANIP|Forward Price to Sales MNKD|AMPH - Price-to-Projected Revenue Ratio|Pacira Pharmaceuticals (PCRX) - Forward Price-to-Revenue Multiple|SPRY: Forward P/S Multiple|Theravance Corp (TBPH) - Forward P/S Multiple|AQST (Aquestive Therapeutics) - Forward P/S Multiple|Forward Price-to-Revenue Multiple Tectonic (TECX)|Forward P/S Multiple TNXP|SXTC - Market Cap to Future Revenue Ratio|Eupraxia Pharmaceuticals Inc. - Forward Price-to-Revenue Multiple|Forward P/S Multiple BioHarvest Sciences Inc BHST|EXOZ: Forward Price-to-Revenue Multiple|Oramed Pharmaceuticals - Price to Expected Revenue Ratio|ENTX: Forward P/S Multiple|HYFT - Market Cap to Expected Sales Ratio|ABVC (ABVC BioPharma Inc) - Forward P/S Multiple|Forward Price-to-Revenue Multiple Cumberland Corp (CPIX)|Forward P/S Multiple QNTM|Forward P/S Multiple fibrogen.com (FGEN)|Price-to-Projected Revenue Ratio Telomir Pharmaceuticals, Inc. TELO|Rani Therapeutics Holdings - Price-to-Projected Revenue Ratio|SNYR - Price-to-Projected Revenue Ratio|Market Cap to Expected Sales Ratio Rallybio Corporation RLYB|LEXX (lexariabioscience.com) - Forward Price-to-Revenue Multiple|pulmatrix.com - Forward Price to Sales|PTHL (Pheton Holdings Limited) - Forward P/S Multiple|Aptorum (APM) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Lyra Therapeutics, Inc (LYRA)|Impact BioMedical, Inc. - Market Cap to Projected Revenue|Forward P/S Multiple TNFA (TNF Pharmaceuticals, Inc.)|YCBD - Forward Price-to-Revenue Multiple|PRFX: Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio Altamira Therapeutics CYTO|Lipella (LIPO) - Price-to-Projected Revenue Ratio|OPTN - Market Cap to Expected Sales Ratio|PIRS (Pieris Pharmaceuticals) - Forward P/S Multiple|Forward Price-to-Revenue Multiple procapsgroup.com (PROC)|Price-to-Projected Revenue Ratio Petros Pharmaceuticals, Inc. (PTPI)|QLI: Future Price to Revenue|Forward P/S Multiple SLRN (ACELYRIN, Inc.)|Forward Price to Sales TFFP
